Patents by Inventor Hisataka Kobayashi
Hisataka Kobayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10537641Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: September 28, 2015Date of Patent: January 21, 2020Assignee: The USA as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 10538590Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: August 21, 2013Date of Patent: January 21, 2020Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20190167793Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: ApplicationFiled: August 7, 2017Publication date: June 6, 2019Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServiceInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
-
Publication number: 20180236076Abstract: It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm?2.Type: ApplicationFiled: August 2, 2016Publication date: August 23, 2018Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human, ServicesInventors: Hisataka Kobayashi, Peter Choyke, Kazuhide Sato, Noriko Sato
-
Publication number: 20170122853Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: ApplicationFiled: August 7, 2015Publication date: May 4, 2017Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Publication number: 20160256564Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: September 28, 2015Publication date: September 8, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Patent number: 9358306Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: June 27, 2012Date of Patent: June 7, 2016Assignee: The United States of America, as rep. by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo
-
Publication number: 20160015829Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: September 28, 2015Publication date: January 21, 2016Inventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20140120119Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: June 27, 2012Publication date: May 1, 2014Applicant: The United States of America, as rep. by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo
-
Publication number: 20130336995Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: August 21, 2013Publication date: December 19, 2013Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga
-
Patent number: 8524239Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: July 11, 2011Date of Patent: September 3, 2013Assignee: The United States of America as represented by the Secrectary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga, Marcelino Bernardo
-
Publication number: 20120010558Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Inventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga, Marcelino Bernardo
-
Patent number: 7846422Abstract: The present invention relates to a method for prevention or treatment of periodontal diseases, containing administering lignans represented by the following formula (1) (wherein R1 represents a hydrogen atom or a hydroxyl group; R2, R3, R4 and R5 are the same or different and each represents a hydrogen atom, a hydroxyl group, a C1-10 alkyl group, a hydroxy C1-10 alkyl group or a C1-10 alkoxy group) or plant extracts containing the lignans.Type: GrantFiled: August 3, 2004Date of Patent: December 7, 2010Assignee: Kao CorporationInventors: Kazushi Oshino, Ikuhisa Ichimura, Hisataka Kobayashi, Minoru Takizawa, Hidetake Fujinaka
-
Publication number: 20100197611Abstract: The present invention relates to an alternative agent with vitamin D-like activity or an improving agent for age-related depression of intestinal function, comprising a sugar-phosphate ester or a salt thereof, as an active ingredient.Type: ApplicationFiled: April 12, 2010Publication date: August 5, 2010Applicant: KAO CORPORATIONInventors: Hidetake FUJINAKA, Junji NAKAMURA, Daiki MURASE, Hatsumi SOUNO, Hisataka KOBAYASHI
-
Publication number: 20060204443Abstract: Methods are disclosed for treating a tumor. A dendrimer conjugate is administered to a subject having a tumor. The dendrimer of the dendrimer conjugate is a generation 5 DAB, generation 2 polylysine, or generation 6-8 PAMAM dendrimer. The dendrimer conjugate comprises an effective amount of an anti-tumor agent. The anti-tumor agent is selectively concentrated in the lymphatic system to treat metastatic disease. In certain examples, the anti-tumor agent is an activatable anti-tumor agent and is activated once the anti-tumor agent is selectively concentrated in the lymphatic system.Type: ApplicationFiled: March 9, 2006Publication date: September 14, 2006Inventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20050171424Abstract: Methods are disclosed for lymphatic system imaging using dendrimer conjugates as contrast agents. The disclosed methods are applicable to the imaging of all lymphatic structures, but in particular embodiments are particularly suited for imaging specific parts of the lymphatic system such as lymph nodes or lymphatic vessels. The methods permit the assessment of abnormal conditions within the lymphatic system, such as lymphoma/lymphoproliferative disease, inflammation, and cancer metastasis. The methods also may be used to identify and locate lymph nodes into which lymph fluid flows from a tumor.Type: ApplicationFiled: January 13, 2004Publication date: August 4, 2005Inventors: Martin Brechbiel, Hisataka Kobayashi, Peter Choyke, John Morris, Thomas Waldmann
-
Publication number: 20050053557Abstract: The present invention relates to a method for prevention or treatment of periodontal diseases, containing administering lignans represented by the following formula (1) (wherein R1 represents a hydrogen atom or a hydroxyl group; R2, R3, R4 and R5 are the same or different and each represents a hydrogen atom, a hydroxyl group, a C1-10 alkyl group, a hydroxy C1-10 alkyl group or a C1-10 alkoxy group) or plant extracts containing the lignans.Type: ApplicationFiled: August 3, 2004Publication date: March 10, 2005Applicant: KAO CORPORATIONInventors: Kazushi Oshino, Ikuhisa Ichimura, Hisataka Kobayashi, Minoru Takizawa, Hidetake Fujinaka
-
Publication number: 20050032710Abstract: The present invention relates to an alternative agent with vitamin D-like activity or an improving agent for age-related depression of intestinal function, comprising a sugar-phosphate ester or a salt thereof, as an active ingredient.Type: ApplicationFiled: May 14, 2004Publication date: February 10, 2005Applicant: KAO CORPORATIONInventors: Hidetake Fujinaka, Junji Nakamura, Daiki Murase, Hatsumi Souno, Hisataka Kobayashi
-
Patent number: 6852842Abstract: Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.Type: GrantFiled: August 26, 2002Date of Patent: February 8, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Robert A. Star, Hisataka Kobayashi
-
Publication number: 20050019267Abstract: Macromolecular imaging agents comprising a polyalkylenimine dendrimer conjugated to a metal chelate are disclosed. In particular embodiment, the imaging agent is a diaminobutane-core polypropylenimine dendrimer having surface amino groups conjugated to gadolinium metal chelates. Administration of this gadolinium conjugate to a subject permits visualization of liver micrometastases as small as about 0.3 mm in a magnetic resonance image of the subject's liver.Type: ApplicationFiled: June 24, 2002Publication date: January 27, 2005Inventors: Martin Brechbiel, Hisataka Kobayashi